With a market value of more than 20 billion Chinese medicine listed companies, how was the first half results?

Pharmaceutical Network Market Analysis: According to the market value of China's Chinese medicine listed enterprises ranked, the current market value of more than 20 billion Chinese medicine listed enterprises have 9, including Yunnan White Medicine, Baiyunshan, Tongrentang, Tianshili, Donga a gum, tablets, step-by-step pharmaceutical, China Resources 39, Yiling Pharmaceuticals.
, how did the performance of these nine Chinese medicine companies in the first half of this year be? At present, Dong'a gum, piece saucy, Yiling Pharmaceuticals has disclosed the semi-annual "report card."
Dong'a gum: Net profit decreased 135%-151% YoY According to the performance forecast disclosed by Dong'a Gum, the company expects to realize a net profit loss of 67.54 million to 98.41 million yuan in January-June this year, down 135%-151% YoY.
compared with the same period last year, when the East Agushan and profit of 192.96 million yuan.
for the reasons for the pre-loss of the results of the report, Dong'a gum said that during the reporting period, especially in the first quarter, some domestic dealers resumed production delays, and pharmacies and other sales places generally low customer flow, resulting in the company's offline business has been greatly affected.
another company is clearing channel inventory, actively strictly control the delivery, comprehensive compression of the channel inventory quantity, so the first half of this year sales have a certain impact.
East A gum is mainly engaged in a gum and a gum products research and development, production and sales business, the company's main products include Agum, people involved in deer antlers.
listed for more than 20 years, The growth of East Agum performance in 2019 "sharp brake."
financial results show that Dong'a gum's 2019 operating income was about RMB2,959 million, down 59.68 percent Year-on-Year, while the corresponding net attributable net profit was RMB444 million, down 121.29 percent YoY.
this is also the first loss since the listing of Dong'a gum.
under the pressure of many aspects, Dong'a gum is also under strategic transformation.
company mentioned in the announcement that it will comprehensively promote channel optimization and establish a consumer-oriented operating system.
: Net profit increased by 15.32% YoY to the 2020 half-year results report showed that the first half of the operating income of 3.246 billion yuan, up 12.15% YoY, net profit of 860 million yuan, up 15.32% YoY.
's revenue growth is mainly due to the strengthening of market planning and expansion of sales channels, the parent company Ofzhou Taipai Pharmaceutical Co., Ltd., the holding subsidiary of Fujian Taipai E-commerce Co., Ltd. (merger) and the holding subsidiary of Fujian Taipa Cosmetics Co., Ltd. (merger) increased sales revenue.
is a company mainly engaged in the production and sale of pharmaceutical products and tourist goods such as ingots, tablets, granules and so on.
main products are the film and its series of products.
Yiling Pharmaceuticals: Net profit increased 50%-60% YoY to The 2020 Interim Results released by Ling PharmaceuticalS.
for the reasons for the first-half earnings growth, The company said in a statement that it was mainly driven by two factors: a significant increase in sales revenue from Lianhua Qing, and a growth in sales revenue for cardiovascular products in the second quarter.
it is understood that from late January 2020, toling Pharmaceuticals will use all its production lines to produce lianhua sage.
Lianhua Qing plague in the first quarter of sales revenue of 1.542 billion yuan, a significant increase in the year-on-year.
data show that the main business of Yiling Pharmaceuticals is the research and development, production and sales of Traditional Chinese medicine.
in recent years, Yiling Pharmaceuticals has increased its research and development efforts year by year, with 515 million yuan invested in research and development in 2019, up 44.34 percent year-on-year, accounting for 8.84 percent of the company's revenue.
the first quarter of this year, research and development costs increased by more than 70% year-on-year, the company's research and development investment and its revenue share in the A-share of the listed companies in China medicine are ranked first.
.